| Project/Area Number |
22650228
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
FUKUDA Shinji 愛媛大学, 医学系研究科, 助教 (70398238)
SAWASAKI Tatsuya 愛媛大学, 無細胞生命科学工学研究センター, 准教授 (50314969)
JOH Takashi 名古屋市立大学, 医学系研究科, 教授 (30231369)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,330,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | がん細胞の特性 / 膜型増殖因子 / HB-EGF / amphiregulin / ER/核膜移行 / レトログレード小胞輸送 / 膜型プロテアーゼ / 抗がん剤抵抗性 / 胃がん / epiregulin / エンドサイトーシス / 核膜移行 / shedding |
|---|
| Research Abstract |
HB-EGF and AREG are synthesized as a membrane-anchored growth factor and expressed at the plasma membrane as pro-forms in normal cells. In some malignant tumor cells in culture, however, proHB-EGF and proAREG trans-locate at the ER/nuclear membrane, which endows resistance for anti-cancer drugs. In this study, we established mouse models bearing tumor expressing proAREG auto-translocation mutant, and showed that the tumor acquired resistance for chemotherapy in vivo. We also tried to identify C-terminal processing proteases of proHB-EGF and proAREG.
|
